Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Vismodegib
Drug ID BADD_D02365
Description Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Indications and Usage Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Marketing Status approved; investigational
ATC Code L01XJ01
DrugBank ID DB08828
KEGG ID D09992
MeSH ID C538724
PubChem ID 24776445
TTD Drug ID D03EDQ
NDC Product Code 50242-140
UNII 25X868M3DS
Synonyms HhAntag691 | NSC 747691 | NSC747691 | NSC-747691 | R 3616 | R3616 cpd | R-3616 | vismodegib | erivedge | GDC 0449 | GDC0449 | GDC-0449 | RG 3616 | RG3616 | RG-3616
Chemical Information
Molecular Formula C19H14Cl2N2O3S
CAS Registry Number 879085-55-9
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pregnancy18.08.02.0040.000392%Not Available
Productive cough22.02.03.0050.000437%
Pruritus23.03.12.001--
Radiculopathy17.10.01.0050.000168%
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.0290.000627%Not Available
Rash maculo-papular23.03.13.0040.000224%
Renal disorder20.01.02.002--Not Available
Respiratory disorder22.02.07.0020.000224%Not Available
Retching07.01.07.0020.000302%Not Available
Rhabdomyolysis15.05.05.0020.000336%
Rhinorrhoea22.12.03.0210.000358%
Sciatica17.10.03.001; 15.10.01.0010.000112%Not Available
Skin cancer23.08.02.002; 16.03.02.0020.000358%Not Available
Skin disorder23.03.03.0070.000437%Not Available
Skin lesion23.03.03.0100.001007%Not Available
Squamous cell carcinoma16.16.01.0020.003850%Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.000750%Not Available
Supraventricular tachycardia02.03.03.0120.000112%
Swollen tongue10.01.05.015; 07.14.02.003; 23.04.01.0140.000358%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000862%
Thinking abnormal19.10.03.001; 17.02.05.0230.000381%Not Available
Tooth loss12.01.17.026; 07.09.09.0010.000492%Not Available
Tumour lysis syndrome14.05.01.004; 16.32.03.0020.000112%
Tumour pain16.32.03.0030.000336%
Visual impairment06.02.10.0130.001366%Not Available
Vomiting07.01.07.0030.007544%
Weight decreased13.15.01.005--
Musculoskeletal disorder15.03.05.025--Not Available
Hypoacusis04.02.01.0060.000302%
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages